[ad_1]
The panic began to rise at the end of the week, but industry professionals are keen to rebadure: no, there is no crisis in the supply of drugs derived from blood. According to Agence France-Presse by Fabrice Pilorgé, director of the French Association of Hemophiliacs, many of these drugs are experiencing supply difficulties, but France is not in a "crisis situation" so far.
This statement comes after a statement issued Wednesday by the National Agency for Safety of Medicines and Health Products (ANSM) on its website, informing of difficulties in supply of seven blood-derived drugs produced by the public biotechnology group LFB. Following a general power cut at the production site of LFB Biomedicaments in Lille, the production line was interrupted, making batches of plasma-derived medicinal products unusable, according to information published on Saturday by Franceinfo.
Read also Vape, effective to stop smoking? AP-HP launches study
However, even if "situations of tension and rupture exist on some of our drugs, for each situation, a solution is found jointly with the ANSM", guaranteed a spokesperson of the group LFB, questioned by Agence France -Press. Dozens of people are affected by the situation, she said. In addition, the biotechnology group "holds only 10% of the market share in drugs for hemophilia type A affected by this situation," said the director of communication of LFB.
No emergency for the weekend
"We are not in a crisis situation where all of a sudden people will find themselves without any solution," confirmed Agence France-Presse the director of the French Association of Hemophiliacs. "It's pretty well managed and it's been anticipated," added Pilorgé, saying the situation was not new. "There is a lot of push for patients to go to their usual treatment center," but "there is no urgency to act during the weekend," he continued.
Read also Gérard Roizès: "The real progress of gene therapies"
A map showing the location of the treatment centers for hemorrhagic diseases (CT-MHC), where patients can be treated, is available on a specialized website (https://mhemo.fr/). "There is no danger in the house, it is necessary to organize specifically to avoid problems, it is something that hospitals and patients can do from the moment they are informed," did he declare.
At the end of December 2017, approximately 15,000 people with rare hemorrhagic disease and more than 7,000 people with hemophilia were identified in France by the FranceCoag network coordinated by the Public Assistance-Hospitals of Marseille.
Source link
